S.-H.I. Ou

456 total citations · 1 hit paper
16 papers, 315 citations indexed

About

S.-H.I. Ou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, S.-H.I. Ou has authored 16 papers receiving a total of 315 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in S.-H.I. Ou's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). S.-H.I. Ou is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (3 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers). S.-H.I. Ou collaborates with scholars based in United States, China and Italy. S.-H.I. Ou's co-authors include Hoda Anton‐Culver, Jason A. Zell, Argyrios Ziogas, Rongxin Zhang, Xiangyu Qiu, Geyan Wu, Xin Jin, Jinrong Zhu, Ticiana Leal and Melissa L. Johnson and has published in prestigious journals such as Oncogene, Annals of Oncology and Biochemical Pharmacology.

In The Last Decade

S.-H.I. Ou

14 papers receiving 313 citations

Hit Papers

Ferroptosis: Emerging mechanisms, biological function, an... 2024 2026 2025 2024 25 50 75
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ferroptosis: Emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation
    2024 77 citations Xin Jin, Xiangyu Qiu et al. Cell Death Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S.-H.I. Ou United States 6 129 128 113 87 84 16 315
Priyanka Bhateja United States 9 120 0.9× 170 1.3× 148 1.3× 82 0.9× 76 0.9× 38 346
Zhe-Sheng Wen China 9 79 0.6× 107 0.8× 170 1.5× 41 0.5× 63 0.8× 11 303
Yunjian Huang China 9 182 1.4× 217 1.7× 65 0.6× 68 0.8× 73 0.9× 30 345
Mike Lau United Kingdom 9 138 1.1× 197 1.5× 173 1.5× 66 0.8× 27 0.3× 25 351
Grégoire Marret France 8 74 0.6× 119 0.9× 96 0.8× 22 0.3× 48 0.6× 24 231
Agustín Sánchez Rey Spain 13 67 0.5× 89 0.7× 123 1.1× 26 0.3× 85 1.0× 22 321
Xingsheng Qiu China 10 88 0.7× 92 0.7× 306 2.7× 32 0.4× 256 3.0× 21 456
Ariane Nguyen United States 5 45 0.3× 213 1.7× 59 0.5× 54 0.6× 66 0.8× 10 319
Xu-Shan Sun France 7 80 0.6× 124 1.0× 36 0.3× 47 0.5× 22 0.3× 13 193
Mingqiu Chen China 11 106 0.8× 107 0.8× 147 1.3× 15 0.2× 78 0.9× 27 358

Countries citing papers authored by S.-H.I. Ou

Since Specialization
Citations

This map shows the geographic impact of S.-H.I. Ou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S.-H.I. Ou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S.-H.I. Ou more than expected).

Fields of papers citing papers by S.-H.I. Ou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S.-H.I. Ou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S.-H.I. Ou. The network helps show where S.-H.I. Ou may publish in the future.

Co-authorship network of co-authors of S.-H.I. Ou

This figure shows the co-authorship network connecting the top 25 collaborators of S.-H.I. Ou. A scholar is included among the top collaborators of S.-H.I. Ou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S.-H.I. Ou. S.-H.I. Ou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Ou, S.-H.I., et al.. (2025). Transforming the “cold” tumors to “hot” tumors: strategies for immune activation. Biochemical Pharmacology. 241. 117194–117194.
2.
Ou, S.-H.I., Xiangyu Qiu, Xin Jin, et al.. (2025). Deciphering the mechanisms of long non-coding RNAs in ferroptosis: insights into its clinical significance in cancer progression and immunology. Cell Death Discovery. 11(1). 14–14. 3 indexed citations
3.
4.
Jin, Xin, Xiangyu Qiu, S.-H.I. Ou, et al.. (2024). Ferroptosis: Emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation. Cell Death Discovery. 10(1). 45–45. 77 indexed citations breakdown →
5.
6.
7.
Gainor, Justin F., Giuseppe Curigliano, Robert C. Doebele, et al.. (2021). OA05.02 Analysis of Resistance Mmechanisms to Pralsetinib in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) from the ARROW Study. Journal of Thoracic Oncology. 16(1). S5–S5. 16 indexed citations
8.
Johnson, Melissa L., S.-H.I. Ou, Minal Barve, et al.. (2020). KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation. European Journal of Cancer. 138. S2–S2. 52 indexed citations
9.
Shaw, Alice T., Gregory J. Riely, Yung‐Jue Bang, et al.. (2019). Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): Overall survival (OS) and updated safety from PROFILE 1001. Annals of Oncology. 30. ii48–ii49. 4 indexed citations
10.
Tiseo, Marcello, Rudolf M. Huber, Maximilian J. Hochmair, et al.. (2017). Brigatinib in ALK+ NSCLC pts with intracranial CNS metastases in 2 clinical trials. Annals of Oncology. 28. ii31–ii31. 2 indexed citations
11.
Ikeda, Sadakatsu, Laurie M. Gay, Dean C. Pavlick, et al.. (2017). Comprehensive Genomic Profiling (CGP) of 114,200 advanced cancers identifies recurrent Kinase Domain Duplications (KDD) and novel oncogenic fusions in diverse tumor types. Annals of Oncology. 28. x1–x1. 3 indexed citations
12.
Halmos, Balázs, Garrett M. Frampton, James Suh, et al.. (2016). Lung sarcomatoid carcinoma (LSC) harbors targetable genomic alterations and high mutational burden as observed by comprehensive genomic profiling (CGP). Annals of Oncology. 27. vi419–vi419. 2 indexed citations
13.
Shaw, Alice T., Gregory J. Riley, Yung‐Jue Bang, et al.. (2016). Crizotinib in advanced ROS1-rearranged non-small cell lung cancer (NSCLC): updated results from PROFILE 1001. Annals of Oncology. 27. vi418–vi418. 14 indexed citations
14.
Soria, J.C., Lecia V. Sequist, Heather A. Wakelee, et al.. (2014). 10LBA Interim phase 2 results of study CO-1686-008: A phase 1/2 study of the irreversible, mutant selective, EGFR inhibitor rociletinib (CO-1686) in patients with advanced non small cell lung cancer. European Journal of Cancer. 50. 199–199. 4 indexed citations
15.
Kris, Mark G., Tony Mok, S.-H.I. Ou, et al.. (2012). First-Line Dacomitinib (PF-00299804), an Irreversible Pan-Her Tyrosine Kinase Inhibitor, for Patients with EGFR-Mutant Lung Cancers. Annals of Oncology. 23. xi34–xi34. 6 indexed citations
16.
Ou, S.-H.I., Jason A. Zell, Argyrios Ziogas, & Hoda Anton‐Culver. (2006). Epidemiology of nasopharyngeal carcinoma in the United States: improved survival of Chinese patients within the keratinizing squamous cell carcinoma histology. Annals of Oncology. 18(1). 29–35. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Priyanka Bhateja Breakdown of academic impact, for papers by Zhe-Sheng Wen Breakdown of academic impact, for papers by Yunjian Huang Breakdown of academic impact, for papers by Mike Lau Breakdown of academic impact, for papers by Grégoire Marret Breakdown of academic impact, for papers by Agustín Sánchez Rey Breakdown of academic impact, for papers by Xingsheng Qiu Breakdown of academic impact, for papers by Ariane Nguyen Breakdown of academic impact, for papers by Xu-Shan Sun Breakdown of academic impact, for papers by Mingqiu Chen
Rankless by CCL
2026